Skip to main content

Table 4 The number of attacks and the treatment characteristics in the three groups of patients

From: Value co-creation in healthcare: evidence from innovative therapeutic alternatives for hereditary angioedema

 

Number of attacks

Number of treated attacks (compliant and non-compliant)

% of treated attacks

Number of vials

Average number of vials per attack

Strategy 1 (home-based)

Icatibant

188

84

44.68%

93

1.11

PdC1-INH

556

435

78.24%

810

1.86

Strategy 2 (hospital-based)

Hospital-based PdC1-INH

54

26

48.15%

67

2.58

Total Strategy 1

744

519

69.76%

903

1.74

Total Strategy 2

54

26

48.15%

67

2.58

  1. pdC1-INH plasma-derived C1-esterase inhibitor concentrate